{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:57:21Z","timestamp":1787237841769,"version":"build-2736575974"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019518","name":"Eli Lilly Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019518","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01425-y","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T23:46:39Z","timestamp":1747352799000},"page":"1719-1754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020\u20132023"],"prefix":"10.1007","volume":"15","author":[{"given":"Julien","family":"Seneschal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"lgnasi","family":"Figueras Nart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manny","family":"Papadimitropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srishti","family":"Dabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lampropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"2","key":"1425_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84\u201392.","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"1425_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","volume":"159","author":"A Mostaghimi","year":"2023","unstructured":"Mostaghimi A, Gao W, Ray M, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol. 2023;159(4):411\u20138.","journal-title":"JAMA Dermatol"},{"key":"1425_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19044","author":"W Chen","year":"2023","unstructured":"Chen W, Li S, Cai X, et al. Association between alopecia areata and atopic dermatitis: current evidence. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19044.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1425_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2023.10.031","volume":"90","author":"MJ Diaz","year":"2024","unstructured":"Diaz MJ, Jaq Z, Abdi P, Tran JT, Guttman-Yassky E, Ungar B. Association between alopecia areata and atopic dermatitis: a nested case-control study of the All of Us database. J Am Acad Dermatol. 2024;90(3):607\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1425_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"1425_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.","journal-title":"Nat Rev Dis Primers"},{"issue":"10247","key":"1425_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"3","key":"1425_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"1425_CR9","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","volume":"12","author":"AN Fasseeh","year":"2022","unstructured":"Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022;12(12):2653\u201368.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1425_CR10","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1425_CR11","doi-asserted-by":"publisher","DOI":"10.2196\/39167","volume":"5","author":"AJ Gilding","year":"2022","unstructured":"Gilding AJ, Ho N, Pope E, Sibbald C. The burden of disease in alopecia areata: Canadian online survey of patients and caregivers. JMIR Dermatol. 2022;5(4):e39167.","journal-title":"JMIR Dermatol"},{"issue":"4","key":"1425_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","volume":"134","author":"SA Mirzoyev","year":"2014","unstructured":"Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990\u20132009. J Invest Dermatol. 2014;134(4):1141\u20132.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1425_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bjd.21055","volume":"187","author":"AE Macbeth","year":"2022","unstructured":"Macbeth AE, Holmes S, Harries M, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022;187(1):73\u201381.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1425_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","volume":"83","author":"E Freitas","year":"2023","unstructured":"Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83(9):761\u201370. https:\/\/doi.org\/10.1007\/s40265-023-01873-w.","journal-title":"Drugs"},{"key":"1425_CR15","doi-asserted-by":"publisher","first-page":"1324892","DOI":"10.3389\/fphar.2024.1324892","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen S, Li C, Tu Z, et al. Off-label use of baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K\/Akt\/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells. Front Pharmacol. 2024;15:1324892. https:\/\/doi.org\/10.3389\/fphar.2024.1324892.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1425_CR16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1425_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase\u00a0III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"18","key":"1425_CR18","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase\u00a03 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"key":"1425_CR19","volume-title":"Olumiant: summary of product characteristics","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. Olumiant: summary of product characteristics. Amsterdam: EMA; 2021."},{"key":"1425_CR20","unstructured":"US Food and Drug Administration. Olumiant: prescribing information. Silver Spring (MD): FDA; 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdf. Accessed 11 April 2024."},{"issue":"3","key":"1425_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"1425_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I \u2013 systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1425_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1425_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase\u00a02 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1425_CR25","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/healthcare9111575","volume":"9","author":"G Radi","year":"2021","unstructured":"Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A. Baricitinib: the first Jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients. Healthcare (Basel). 2021;9(11):1575.","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"1425_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase\u00a0III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23\u201332.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1425_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1172\/JCI129197","volume":"130","author":"VA Rudrapatna","year":"2020","unstructured":"Rudrapatna VA, Butte AJ. Opportunities and challenges in using real-world data for health care. J Clin Invest. 2020;130(2):565\u201374.","journal-title":"J Clin Invest"},{"key":"1425_CR28","unstructured":"European Medicines Agency. Data analysis and real world interrogation network (DARWIN EU). Amsterdam: EMA; 2022. https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/big-data\/data-analysis-real-world-interrogation-network-darwin-eu. Accessed 11 April 2024."},{"key":"1425_CR29","unstructured":"US Food & Drug Administration. Real-world evidence. Silver Spring (MD): FDA; 2022. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence. Accessed 11 April 2024."},{"issue":"3","key":"1425_CR30","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1111\/ijd.15644","volume":"61","author":"E Cinelli","year":"2022","unstructured":"Cinelli E, Fabbrocini G, Megna M. Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation. Int J Dermatol. 2022;61(3):e107\u20138.","journal-title":"Int J Dermatol"},{"key":"1425_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"1425_CR32","volume-title":"Methods for the development of NICE public health guidance","author":"National Institute for Health and Care Excellence","year":"2012","unstructured":"National Institute for Health and Care Excellence. Methods for the development of NICE public health guidance. London: NICE; 2012."},{"key":"1425_CR33","unstructured":"Lim JH, Kwon SH, Sim WY, Lew BL. Real-world experience of baricitinib in Korean patients with moderate to severe atopic dermatitis. 12th Georg Rajka international symposium on atopic dermatitis; October 17\u201319, 2022; Montr\u00e9al, QC."},{"key":"1425_CR34","doi-asserted-by":"crossref","unstructured":"Augustin M, Nosbaum A, Thyssen JP, et al. Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional patient survey. EADV symposium; May\u00a018\u201320, 2023; Seville.","DOI":"10.1080\/09546634.2023.2276047"},{"key":"1425_CR35","unstructured":"Nosbaum A, Lampropoulou T, Grond S, et al. Patient beliefs on atopic dermatitis from a baricitinib treatment satisfaction survey in France, Germany and the United Kingdom. EADV congress; October 11\u201314, 2023; Berlin."},{"key":"1425_CR36","unstructured":"Pinter A, Reguiai Z, Werfel T, et al. Baricitinib outcomes on atopic dermatitis lesion locations: results from a cross-sectional patient survey in France, Germany and the United Kingdom. EADV congress; October 11\u201314, 2023; Berlin."},{"key":"1425_CR37","unstructured":"Pinter A, Sondermann W, Maintz L, et al. Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in Germany: final results from a cross-sectional patient survey. EADV congress; October 11\u201314, 2023; Berlin."},{"key":"1425_CR38","unstructured":"Seneschal J, Eyerich K, Ameen M, et al. Treatment patterns and patient satisfaction with baricitinib on the abbreviated treatment satisfaction questionnaire for medication in moderate-to-severe atopic dermatitis: patient survey in France, Germany, and the United Kingdom. EADV symposium; May\u00a018\u201320, 2023; Seville."},{"key":"1425_CR39","unstructured":"Gkini MA. Effectiveness and safety of baricitinib for severe alopecia areata in a real-world setting. 25th world congress of dermatology; July 3\u20138, 2023; Singapore."},{"key":"1425_CR40","unstructured":"Uchida H, Kamata M, Egawa S, et al. Further rapid improvement of alopecia areata by upadacitinib treatment after incomplete amelioration by 9-month baricitinib treatment in a patient with atopic dermatitis. EADV congress; October 11\u201314, 2023; Berlin."},{"key":"1425_CR41","doi-asserted-by":"publisher","first-page":"adv00677","DOI":"10.2340\/actadv.v102.1088","volume":"102","author":"D Rogner","year":"2022","unstructured":"Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol. 2022;102:adv00677.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1425_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jdermsci.2022.04.006","volume":"106","author":"A Uchiyama","year":"2022","unstructured":"Uchiyama A, Fujiwara C, Inoue Y, Ishikawa M, Motegi S-I. Possible suppressive effects of baricitinib on serum IL-22 levels in atopic dermatitis. J Dermatol Sci. 2022;106(3):189\u201392.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"1425_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/1346-8138.16350","volume":"49","author":"A Uchiyama","year":"2022","unstructured":"Uchiyama A, Fujiwara C, Inoue Y, Motegi S-I. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J Dermatol. 2022;49(4):469\u201371.","journal-title":"J Dermatol"},{"key":"1425_CR44","unstructured":"Augustin M, Bewley A, Reed C, et al. Initial report from the AD-REAL study on baseline characteristics and Week\u00a012 results in patients with moderate-to-severe atopic dermatitis treated with baricitinib and other oral systemic treatments in real-world clinical practice. EADV symposium; May\u00a018\u201320, 2023; Seville."},{"issue":"4","key":"1425_CR45","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jaci.2023.06.004","volume":"152","author":"A Fayand","year":"2023","unstructured":"Fayand A, Hentgen V, Posseme C, et al. Successful treatment of JAK1-associated inflammatory disease. J Allergy Clin Immunol. 2023;152(4):972\u201383.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1425_CR46","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.16763","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869\u201379.","journal-title":"J Dermatol"},{"key":"1425_CR47","doi-asserted-by":"publisher","first-page":"adv14153","DOI":"10.2340\/actadv.v103.14153","volume":"103","author":"Z Reguiai","year":"2023","unstructured":"Reguiai Z, Becherel PA, Perrot JL, et al. Impact of baricitinib on patients\u2019 quality of life after one year of treatment for atopic dermatitis in real-world practice: results of the observatory of chronic inflammatory skin diseases REGISTRY. Acta Derm Venereol. 2023;103:adv14153.","journal-title":"Acta Derm Venereol"},{"key":"1425_CR48","doi-asserted-by":"crossref","unstructured":"Watanabe A, Kamata M, Ishikawa T, et al. Real-world effectiveness and safety of baricitinib and its effect on biomarkers and laboratory data concerning its safety in Japanese adult patients with atopic dermatitis: a single-center retrospective study. EADV congress; October 11\u201314, 2023; Berlin.","DOI":"10.3389\/jcia.2024.12455"},{"issue":"4","key":"1425_CR49","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1111\/jdv.18804","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Elberling J, Skov L, et al. Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(4):e543\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1425_CR50","unstructured":"Hong N, Park SY, Kook H, et al. Baricitinib as a useful treatment for mild-to-moderate atopic dermatitis: a real-world experience. 13th Georg Rajka international symposium; August 31\u2013September 2, 2023; Gda\u0144sk."},{"key":"1425_CR51","unstructured":"Boesjes CM, Kamphuis E, Zuithoff P, et al. Real-world evidence of baricitinib and upadacitinib treatment in patients with very difficult-to-treat atopic dermatitis. 31st EADV congress, September 7\u201310, 2022; Milan."},{"key":"1425_CR52","doi-asserted-by":"publisher","first-page":"adv00820","DOI":"10.2340\/actadv.v102.3978","volume":"102","author":"CM Boesjes","year":"2022","unstructured":"Boesjes CM, Kamphuis E, Zuithoff NPA, et al. Daily practice experience of baricitinib treatment for patients with difficult-to-treat atopic dermatitis: results from the BioDay registry. Acta Derm Venereol. 2022;102:adv00820.","journal-title":"Acta Derm Venereol"},{"key":"1425_CR53","unstructured":"Kook DH, Park SY, Hong N, et al. Combination therapy of dupilumab and baricitinib for the treatment of atopic dermatitis dupilumab baricitinib. 12th Georg Rajka international symposium on atopic dermatitis. October 17\u201319, 2022; Montr\u00e9al, QC."},{"key":"1425_CR54","unstructured":"Ra A, Coe J, Bennett H, et al. Baricitinib for the treatment of recalcitrant, moderate-to-severe atopic dermatitis: real-world experience from two tertiary UK dermatology centers. 31st EADV congress, September 7\u201310, 2022; Milan."},{"key":"1425_CR55","unstructured":"Schlosser A, De Wijs L, Schreurs C, et al. Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: first daily practice results. 31st EADV congress, September 7\u201310, 2022; Milan."},{"key":"1425_CR56","unstructured":"Traidl S, Siegels D, Heinrich L, et al. Janus kinase inhibitor baricitinib for the treatment of atopic dermatitis - first report from the German national registry TREATgermany. 31st EADV congress, September 7\u201310, 2022; Milan."},{"key":"1425_CR57","unstructured":"Maintz L, Hermann N, Havenith R, et al. Real-world data on short-term effectiveness, clinician- and patient-reported outcomes in patients with atopic dermatitis treated with baricitinib. Abstract 1521. EADV symposium; May\u00a018\u201320, 2023; Seville."},{"issue":"1","key":"1425_CR58","doi-asserted-by":"publisher","first-page":"2276047","DOI":"10.1080\/09546634.2023.2276047","volume":"34","author":"M Augustin","year":"2023","unstructured":"Augustin M, Nosbaum A, Werfel T, et al. Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey. J Dermatolog Treat. 2023;34(1):2276047.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1425_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15525","volume":"35","author":"HD Kook","year":"2022","unstructured":"Kook HD, Hong N, Lee DH, et al. The effect of baricitinib add-on therapy in atopic dermatitis patients treated with dupilumab. Dermatol Ther. 2022;35(7):e15525.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1425_CR60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/ajd.14074","volume":"64","author":"SD Lee","year":"2023","unstructured":"Lee SD, Ahn H-J, Shin MK. Nine cases of chronic hand and foot eczema treated with baricitinib. Australas J Dermatol. 2023;64(3):408\u201312.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"1425_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14818","volume":"34","author":"J-C Chen","year":"2021","unstructured":"Chen J-C, Lian C-H. Case report: baricitinib combined with adjuvant therapy for treatment of atopic dermatitis in a child. Dermatol Ther. 2021;34(2):e14818.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1425_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14878","volume":"34","author":"Y He","year":"2021","unstructured":"He Y, Ji S, Yu Q. Effectiveness of baricitinib in prurigo-type atopic dermatitis: a case report. Dermatol Ther. 2021;34(2):e14878.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1425_CR63","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1111\/1346-8138.16024","volume":"48","author":"H Uchida","year":"2021","unstructured":"Uchida H, Kamata M, Nagata M, et al. Baricitinib improved alopecia areata concomitant with atopic dermatitis: a case report. J Dermatol. 2021;48(9):e472\u20133.","journal-title":"J Dermatol"},{"issue":"3","key":"1425_CR64","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1093\/rheumatology\/keab771","volume":"61","author":"L De Stefano","year":"2022","unstructured":"De Stefano L, Bobbio-Pallavicini F, Montecucco C, Bugatti S. Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib. Rheumatology (Oxford). 2022;61(3):e64\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1425_CR65","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1684\/ejd.2022.4337","volume":"32","author":"R Honda","year":"2022","unstructured":"Honda R, Suenaga A, Nakahara T, Shibata-Kikuchi S. Atopic dermatitis refractory to dupilumab but markedly responsive to baricitinib. Eur J Dermatol. 2022;32(5):649\u201350.","journal-title":"Eur J Dermatol"},{"issue":"11","key":"1425_CR66","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15802","volume":"35","author":"DH Lee","year":"2022","unstructured":"Lee DH, Park SY, Hong N, et al. Successful treatment of atopic dermatitis refractory to dupilumab with baricitinib. Dermatol Ther. 2022;35(11):e15802.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1425_CR67","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/cod.14039","volume":"86","author":"FM Rosenberg","year":"2022","unstructured":"Rosenberg FM, Loman L, Schuttelaar MLA. Baricitinib treatment of severe chronic hand eczema: two case reports. Contact Dermatitis. 2022;86(5):419\u201321.","journal-title":"Contact Dermatitis"},{"issue":"9","key":"1425_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15724","volume":"35","author":"D Xia","year":"2022","unstructured":"Xia D, Xiao Y, Li M, Li W. Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib. Dermatol Ther. 2022;35(9):e15724.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1425_CR69","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1111\/1346-8138.16724","volume":"50","author":"M Ueda","year":"2023","unstructured":"Ueda M, Kogame T, Egawa G, Kambe N, Kabashim K. A case of Kimura disease with atopic dermatitis successfully treated with baricitinib. J Dermatol. 2023;50(6):e196\u20137.","journal-title":"J Dermatol"},{"issue":"2","key":"1425_CR70","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ad.2022.06.024","volume":"115","author":"M Pestana","year":"2024","unstructured":"Pestana M, Brito CM, Duarte B. Atopic dermatitis and multilocular alopecia areata simultaneously treated with baricitinib. Actas Dermosifiliogr. 2024;115(2):200\u20131.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"1425_CR71","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/pde.15386","volume":"41","author":"B Dhir","year":"2024","unstructured":"Dhir B, Meena SK, Sardana K, Sharath S. Use of tofacitinib in baricitinib-refractory atopic dermatitis: an example of JAK inhibitor switching. Pediatr Dermatol. 2024;41(1):139\u201340.","journal-title":"Pediatr Dermatol"},{"key":"1425_CR72","unstructured":"Ran Y. Oral JAK inhibitor baricitinib for alopecia areata: a real-world study. 25th world congress of dermatology; July 3\u20138, 2023; Singapore."},{"key":"1425_CR73","unstructured":"Choi S-M, Lim J-H, Park S, et al. Real-world effectiveness and safety of baricitinib in patients with alopecia areata. EADV congress; October 11\u201314, 2023; Berlin."},{"issue":"11","key":"1425_CR74","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s13555-023-01030-x","volume":"13","author":"A De Greef","year":"2023","unstructured":"De Greef A, Thirion R, Ghislain P-D, Baeck M. Real-life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1-year follow-up data. Dermatol Ther (Heidelb). 2023;13(11):2869\u201377.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1425_CR75","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/ced\/llad239","volume":"48","author":"V H\u00e9bert","year":"2023","unstructured":"H\u00e9bert V, Joly P. Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series. Clin Exp Dermatol. 2023;48(11):1258\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1425_CR76","doi-asserted-by":"publisher","first-page":"2268764","DOI":"10.1080\/09546634.2023.2268764","volume":"34","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Vignoli CA, et al. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J Dermatolog Treat. 2023;34(1):2268764.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1425_CR77","doi-asserted-by":"publisher","first-page":"AB152","DOI":"10.1016\/j.jaad.2023.07.610","volume":"89","author":"MA Gkini","year":"2023","unstructured":"Gkini MA, Tagka P, Rigatos T, Papakonstantis M. Early real-world experience with baricitinib in the treatment of severe alopecia areata [abstract 43696]. J Am Acad Dermatol. 2023;89(3):AB152.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 4","key":"1425_CR78","doi-asserted-by":"publisher","first-page":"ljad113.168","DOI":"10.1093\/bjd\/ljad113.168","volume":"188","author":"MA Gkini","year":"2023","unstructured":"Gkini MA, Tagka P, Rigatos T, Papakonstantis M. BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience. Br J Dermatol. 2023;188(Suppl 4):ljad113.168.","journal-title":"Br J Dermatol"},{"key":"1425_CR79","unstructured":"Mukahal A, Moneer B, Fathi B, et al. Successful treatment of alopecia universalis with baricitinib in Libyan patients. Skin inflammation & psoriasis international network 7th congress; July 6\u20138, 2022; Paris."},{"issue":"Suppl 1","key":"1425_CR80","first-page":"38","volume":"63","author":"A Moussa","year":"2022","unstructured":"Moussa A, Bhoyrul B, Sinclair R. Combination treatment of alopecia areata of the beard with baricitinib and minoxidil. Australas J Dermatol. 2022;63(Suppl 1):38.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"1425_CR81","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaad.2022.11.028","volume":"88","author":"A Moussa","year":"2023","unstructured":"Moussa A, Eisman S, Sinclair RD, Bhoyrul B. Treatment of alopecia areata of the beard with baricitinib. J Am Acad Dermatol. 2023;88(4):948\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1425_CR82","unstructured":"Puerto AARD, Neila RB, Andujar MM, et al. Real world practice indirect comparison between baricitinib and tofacitinib for severe alopecia areata : results from an Spanish third level hospital retrospective study. EADV congress; October 11\u201314, 2023; Berlin."},{"issue":"12","key":"1425_CR83","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15845","volume":"35","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu T, Li S, et al. Efficacy and safety of baricitinib in patients with refractory alopecia areata. Dermatol Ther. 2022;35(12):e15845.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1425_CR84","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jaad.2023.03.041","volume":"89","author":"A Kazmi","year":"2023","unstructured":"Kazmi A, Moussa A, Bokhari L, et al. Switching between tofacitinib and baricitinib in alopecia areata: a review of clinical response. J Am Acad Dermatol. 2023;89(6):1248\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1425_CR85","unstructured":"Moussa A, Bhoyrul B, Sinclair R. Combination treatment of moderate-to-severe alopecia areata in adolescent patients with baricitinib and minoxidil. Australasian College of Dermatologists 54th annual scientific meeting, discover connect collaborate; April 30\u2013May\u00a03, 2022; Adelaide."},{"issue":"2","key":"1425_CR86","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/bjd\/ljad118","volume":"189","author":"L Asfour","year":"2023","unstructured":"Asfour L, Bokhari L, Bhoyrul B, et al. Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib. Br J Dermatol. 2023;189(2):248\u201350.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1425_CR87","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jaad.2022.12.033","volume":"88","author":"A Moussa","year":"2023","unstructured":"Moussa A, Eisman S, Kazmi A, et al. Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: a retrospective review of 29 patients. J Am Acad Dermatol. 2023;88(5):1194\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1425_CR88","doi-asserted-by":"publisher","first-page":"e1085","DOI":"10.1111\/jdv.19121","volume":"37","author":"J Zhan","year":"2023","unstructured":"Zhan J, Cao J, Chen F, Jin Y, Huang C. Real-data on the use of baricitinib in adolescents with severe alopecia areata. J Eur Acad Dermatol Venereol. 2023;37(8):e1085\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1425_CR89","unstructured":"Willems A, Sinclair R. Oral baricitinib and sublingual minoxidil for alopecia universalis in an 11-year-old girl: a novel combination therapy for paediatric patients. Australasian College of Dermatologists 54th annual scientific meeting, discover connect collaborate; April 30\u2013May\u00a03, 2022; Adelaide."},{"key":"1425_CR90","doi-asserted-by":"publisher","first-page":"1253795","DOI":"10.3389\/fmed.2023.1253795","volume":"10","author":"L Cai","year":"2023","unstructured":"Cai L, Wei Y, Zhao M, Zhuo J, Tao X, Lin M. Case report: dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib. Front Med (Lausanne). 2023;10:1253795.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"1425_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15728","volume":"35","author":"N Hong","year":"2022","unstructured":"Hong N, Park SY, Kook HD, et al. Baricitinib rapidly relieves eczema associated pruritus in elderly patients. Dermatol Ther. 2022;35(9):e15728.","journal-title":"Dermatol Ther"},{"key":"1425_CR92","unstructured":"Lew BL, Lim J-H, Kwon S-H, et al. Real-world experience of baricitinib in korean patients with atopic dermatitis. 31st EADV congress, September 7\u201310, 2022; Milan."},{"issue":"10","key":"1425_CR93","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1159\/000530394","volume":"184","author":"B Liu","year":"2023","unstructured":"Liu B, Song X, Liao S, Luan T, Zhao Z. Comparison of efficacy of baricitinib and dupilumab in the treatment of Chinese moderate-to-severe atopic dermatitis: a retrospective study. Int Arch Allergy Immunol. 2023;184(10):966\u201374.","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"1425_CR94","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jaad.2022.10.034","volume":"88","author":"J Vanlerberghe","year":"2023","unstructured":"Vanlerberghe J, Dezoteux F, Martin C, et al. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2023;88(4):900\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"1425_CR95","unstructured":"Castronovi C, Ambrogio F, Foti C, et al. The impact of baricitinib therapy on alopecia areata. EADV congress; October 11\u201314, 2023; Berlin."},{"key":"1425_CR96","unstructured":"Yew YW, Yeo FPM, Thng STG. Efficacy and adverse effects of oral JAK inhibitors in the treatment of atopic dermatitis: an initial real-world experience in an Asian clinical cohort. 25th world congress of dermatology; July 3\u20138, 2023; Singapore."},{"issue":"11","key":"1425_CR97","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1111\/1346-8138.16893","volume":"50","author":"H Uchida","year":"2023","unstructured":"Uchida H, Kamata M, Watanabe A, et al. Improvement of severe alopecia areata after 9-month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis. J Dermatol. 2023;50(11):e392\u20133.","journal-title":"J Dermatol"},{"key":"1425_CR98","unstructured":"Park SY, Hong N, Kook HD, et al. A case of atopic dermatitis refractory to baricitinib successfully treated with upadacitinib. 12th Georg Rajka international symposium on atopic dermatitis. October 17\u201319, 2022; Montr\u00e9al, QC."},{"issue":"4","key":"1425_CR99","first-page":"e493","volume":"37","author":"C Valente","year":"2022","unstructured":"Valente C, Duarte B. Erythrodermic atopic dermatitis resistant to dupilumab and baricitinib successfully treated with upadacitinib. J Eur Acad Dermatol Venereol. 2022;37(4):e493\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1425_CR100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdcr.2022.09.029","volume":"30","author":"SD Lee","year":"2022","unstructured":"Lee SD, Ahn H-J, Shin MK. A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis. JAAD Case Rep. 2022;30:11\u20136.","journal-title":"JAAD Case Rep"},{"issue":"10","key":"1425_CR101","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"PA Lio","year":"2020","unstructured":"Lio PA, Wollenberg A, Thyssen JP, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1425_CR102","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/derm.2022.29015.jsi","volume":"34","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Mohawk JA, Cirulli J, et al. Burden of disease and unmet needs in atopic dermatitis: results from a patient survey. Dermatitis. 2023;34(2):135\u201344.","journal-title":"Dermatitis"},{"issue":"8","key":"1425_CR103","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1007\/s12325-023-02528-8","volume":"40","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, de Bruin-Weller M, Costanzo A, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week\u00a016. Adv Ther. 2023;40(8):3574\u201387.","journal-title":"Adv Ther"},{"issue":"5","key":"1425_CR104","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/1346-8138.15817","volume":"48","author":"YR Woo","year":"2021","unstructured":"Woo YR, Han Y, Lee JH, et al. Real-world prevalence and burden of genital eczema in atopic dermatitis: a multicenter questionnaire-based study. J Dermatol. 2021;48(5):625\u201332. https:\/\/doi.org\/10.1111\/1346-8138.15817.","journal-title":"J Dermatol"},{"key":"1425_CR105","unstructured":"Maintz L, Schmitz M-T, Herrmann N, et al. Real-world data on short-term effectiveness, clinician- and patient-reported outcomes in patients with atopic dermatitis treated with baricitinib [poster]. EADV Symposium; May\u00a018\u201320, 2023; Seville."},{"issue":"4","key":"1425_CR106","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1684\/ejd.2022.4280","volume":"32","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Lio P, Kleyn E, et al. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five phase\u00a0III clinical trials. Eur J Dermatol. 2022;32(4):522\u20139.","journal-title":"Eur J Dermatol"},{"key":"1425_CR107","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s13555-024-01171-7","volume":"14","author":"JM Carrascosa","year":"2024","unstructured":"Carrascosa JM, Narcisi A, Nomura T, et al. Baricitinib improvement across regions in atopic dermatitis patients with baseline body surface area up to 40% and severe itch. Dermatol Ther (Heidelb). 2024;14:1561\u201373.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1425_CR108","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104\u00a0weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1425_CR109","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. Management of patients affected by moderate to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi consensus. Dermatol Ther (Heidelb). 2024;14(4):919\u201332.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1425_CR110","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000479722","volume":"4","author":"Y Ramot","year":"2017","unstructured":"Ramot Y, Zlotogorski A. Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient. Skin Appendage Disord. 2017;4(2):122\u20134.","journal-title":"Skin Appendage Disord"},{"key":"1425_CR111","unstructured":"ClinicalTrials.gov. 2024. A study of baricitinib (LY3009104) in children from 6\u00a0years to less than 18\u00a0years of age with alopecia areata (BRAVE-AA-PEDS). NCT05723198. https:\/\/clinicaltrials.gov\/study\/NCT05723198. Accessed 11 April 2024."},{"issue":"1","key":"1425_CR112","doi-asserted-by":"publisher","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","volume":"34","author":"T Bieber","year":"2023","unstructured":"Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6\u00a0years and up to 3.9\u00a0years of treatment: an updated integrated analysis of eight clinical trials. J Dermatol Treat. 2023;34(1):2161812.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"1425_CR113","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218\u201327.","journal-title":"Br J Dermatol"},{"key":"1425_CR114","unstructured":"Costanzo A, Torrelo A, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 and up to 4.6\u00a0years treatment: final integrated analysis of 8 clinical trials. EADV congress; September 25\u201328, 2024; Amsterdam."},{"key":"1425_CR115","unstructured":"European Medicines Agency. Olumiant: procedural steps taken and scientific information after the authorisation. Amsterdam: EMA; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/olumiant-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 02 Aug 2024."},{"issue":"1","key":"1425_CR116","doi-asserted-by":"publisher","first-page":"2411834","DOI":"10.1080\/09546634.2024.2411834","volume":"35","author":"A Wollenberg","year":"2024","unstructured":"Wollenberg A, Ikeda M, Chu CY, et al. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18\u00a0years old: a randomized clinical trial of extended treatment to 3.6\u00a0years. J Dermatol Treat. 2024;35(1):2411834.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"1425_CR117","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s43441-023-00544-y","volume":"57","author":"V Acha","year":"2023","unstructured":"Acha V, Barefoot B, Juarez Garcia A, et al. Principles for good practice in the conduct of non-interventional studies: the view of industry researchers. Ther Innov Regul Sci. 2023;57(6):1199\u2013208.","journal-title":"Ther Innov Regul Sci"},{"issue":"11","key":"1425_CR118","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39(11):4910\u201360. https:\/\/doi.org\/10.1007\/s12325-022-02281-4.","journal-title":"Adv Ther"},{"key":"1425_CR119","unstructured":"Fougerousse AC, Perrot JL, Reguiai Z, et al. Comparison of patient\u2019s profile initiating anticytokines and JAK inhibitors for atopic dermatitis in the OMCCI cohort. 31st EADV congress, September 7\u201310, 2022; Milan, Italy."},{"issue":"1","key":"1425_CR120","doi-asserted-by":"publisher","first-page":"2276043","DOI":"10.1080\/09546634.2023.2276043","volume":"34","author":"T Hagino","year":"2023","unstructured":"Hagino T, Yoshida M, Hamada R, et al. Effectiveness of switching from baricitinib 4\u00a0mg to upadacitinib 30\u00a0mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J Dermatolog Treat. 2023;34(1):2276043.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1425_CR121","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15351","volume":"35","author":"Z Fiocco","year":"2022","unstructured":"Fiocco Z, Kerl K, French LE. Disseminated tinea corporis under baricitinib therapy for atopic dermatitis. Dermatol Ther. 2022;35(4):e15351.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1425_CR122","doi-asserted-by":"publisher","first-page":"535","DOI":"10.23736\/S2784-8671.22.07348-0","volume":"157","author":"A Dattola","year":"2023","unstructured":"Dattola A, Pensa C, Chimenti MS, et al. Baricitinib effectiveness in patients with alopecia universalis and rheumatoid arthritis. Ital J Dermatol Venereol. 2023;157(6):535\u20136.","journal-title":"Ital J Dermatol Venereol"},{"issue":"12","key":"1425_CR123","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15953","volume":"35","author":"T Seo","year":"2022","unstructured":"Seo T, Izumi K, Kawamura T, et al. A case of atopic dermatitis-associated dupilumab-resistant alopecia totalis successfully treated with baricitinib. Dermatol Ther. 2022;35(12):e15953.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1425_CR124","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.annder.2023.02.001","volume":"150","author":"S Rotaru","year":"2023","unstructured":"Rotaru S, Common M, Mah\u00e9 E. Severe inflammatory tinea capitis in a child receiving baricitinib therapy for alopecia areata. Ann Dermatol Venereol. 2023;150(2):160\u20131.","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"1425_CR125","first-page":"63","volume":"1","author":"E Tampouratzi","year":"2024","unstructured":"Tampouratzi E, Sfaelos K, Pizimola M, Rigatos P, Katsantonis J. Baricitinib demonstrates rapid action within just 2\u00a0months of treatment in severe and unresponsive alopecia areata: a case report. Dermatol AMJ. 2024;1(1):63\u20137.","journal-title":"Dermatol AMJ"},{"issue":"8","key":"1425_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13425","volume":"29","author":"YG Koh","year":"2023","unstructured":"Koh YG, Han HS, Seok J, et al. Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis. Skin Res Technol. 2023;29(8):e13425.","journal-title":"Skin Res Technol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01425-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T07:02:46Z","timestamp":1748674966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01425-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":126,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01425-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Julien Seneschal has received support for attending meetings and\/or travel from Eli Lilly and Company, and consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, abstract (and subsequent poster) writing, or educational events from AbbVie, Pfizer, Almirall, Eli Lilly and Company, and Sanofi. lgnasi Figueras Nart has received consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, abstract (and subsequent poster) writing, or educational events, and support for attending meetings and\/or travel from AbbVie, Eli Lilly and Company, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, and Vifor Pharma. Manny Papadimitropoulos, Silvia Sabatino, and Srishti Dabral are employees and minor stakeholders of Eli Lilly and Company. Anastasia Lampropoulou is a former employee and former minor stakeholder of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This was a systematic review of the literature, so no ethical approval was required. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}